QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 abvc-biopharma-q2-eps-013-down-from-009-yoy

ABVC BioPharma (NASDAQ:ABVC) reported quarterly losses of $(0.13) per share. This is a 44.44 percent decrease over losses of $(...

 abvc-biopharma-secures-japanese-patent-for-its-natural-mdd-treatment-candidate-abv-1504

ABVC BioPharma, Inc. (NASDAQ:ABVC), a clinical-stage biopharmaceutical company developing botanical-based therapies for central...

 abvc-biopharma-determined-that-it-has-a-material-weakness-in-its-internal-controls-over-financial-reporting-concluded-that-financial-statements-for-fy-ended-dec-31-2023-should-no-longer-be-relied-upon-due-to-errors-in-financial-statements

- SEC Filing

 abvc-biopharmas-leeds-chow-resigns-as-cfo-ceo-uttam-patil-to-serve-as-interim-cfo

- SEC Filing

 abvc-biopharma-seeks-to-revolutionize-mental-health-treatment-with-a-safe-prozac-alternative-boasting-a-madrs-score-reduction-of--1321-from-baseline-over-6-weeks-with-a-placebo-subtracted-difference-of--41

ABVC BioPharma, Inc. (NASDAQ:ABVC), a clinical-stage biopharmaceutical company focused on innovative treatments in ophthalmolog...

 abvc-biopharma-reveals-receipt-of-200k-cash-payment-from-oncox-biopharma-as-part-of-its-strategic-licensing-agreement-for-certain-oncology-related-products

This payment marks the first installment of $5 million in potential licensing fees from OncoX.With this payment, the total accu...

 abvc-biopharma-receives-50000-in-incremental-licensing-fees

With this payment, ABVC has received a total of $346,000 in licensing fees from its strategic partners, supporting our partner&...

 abvc-biopharma-got-written-notification-from-nasdaq-indicating-co-regained-compliance-with-listing-rules-5635a1-and-5635a2

- SEC Filing

 abvc-biopharma--biolite-entered-into-definitive-agreement-with-oncox-biopharma-to-collaborate-on-combination-therapy-abvc--unit-are-eligible-to-receive-aggregate-license-fee-of-125m-in-form-of-cash-or-shares-of-oncox-securities-under-terms-of-deal-abvc-grants-oncox-exclusive-rights-for-one-of-abvcs-4-products-in-its-oncology-pipeline

- SEC Filing 

 abvc-biopharma-collaboration-between-abvc-and-oncox-biopharma-abvc-expecting-aggregate-income-of-1375m-and-royalties-of-up-to-1250m-grants-oncox-exclusive-rights-for-one-of-abvcs-four-products-in-its-oncology-pipeline-to-develop-manufacture-commercialize-blex-404

https://www.sec.gov/ix?doc=/Archives/edgar/data/1173313/000121390024041053/ea0205569-8k_abvcbio.htm

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION